Clinical Trials

1,946 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07287098 2026-04-17

preEMBER

600 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07535905 2026-04-17

REVIVE

96 enrolled

Genitourinary

Hypogonadism, Prostatic Neoplasms

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT04852887 2026-04-15

DEBRA

Phase 3 Recruiting

1,670 enrolled

Breast Neoplasms

NCT01127295 2026-04-14

PHACS

Phase 4 Completed

2,000 enrolled

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Phase 4 Completed

29 enrolled

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Phase 4 Completed

39 enrolled

Breast Neoplasms

NCT00310180 2026-04-13

TAILORx

10,273 enrolled 14 charts

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

5,018 enrolled 14 charts

Phase 2 Active not recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT02311933 2026-04-13

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

81 enrolled 9 charts

Breast Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT05774951 2026-04-13

CAMBRIA-1

Phase 3 Recruiting

4,300 enrolled

Breast Neoplasms

NCT05941520 2026-04-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

80 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-04-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

200 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06195306 2026-04-13

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

66 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06979596 2026-04-13

OMAHA-015

250 enrolled

Tumor-Agnostic

Neoplasms

NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Phase 2 Active not recruiting

984 enrolled

Hot Flashes

NCT04569747 2026-04-02

ADEPT

393 enrolled

Phase 4 Active not recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

8,000 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07499999 2026-03-30

BabyTEARS

140 enrolled

Breast Neoplasms, Carcinoma, Ductal

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

4,220 enrolled